The median OS was 24.6 months (95 % CI, 20.7–28.5) in patients with plasma EGFR 19DEL or L859R mutations and 27.0 months (95 % CI, 25.0–29.0)) in patients with these mutations in their tumor tissue. This evidence concerns the gene EGFR and neoplasm.